Ainos Inc. Announces Breakthrough Interim Results in VELDONA Clinical Trial for Feline Chronic Gingivostomatitis, Signaling New Era in Companion Animal Immunotherapy

Reuters

2025/05/19

Ainos Inc. Announces Breakthrough Interim Results in VELDONA Clinical Trial for Feline Chronic Gingivostomatitis, Signaling New Era in Companion Animal Immunotherapy

Ainos Inc., a San Diego-based biotech company, has announced interim results from its ongoing clinical trial of VELDONA, a low-dose oral interferon therapy, for treating Feline Chronic Gingivostomatitis (FCGS), a chronic inflammatory condition in cats. The trial involves 30 cats and aims to assess inflammation scores, corticosteroid usage, and treatment safety. Early results show significant improvements in inflammation and a reduction in steroid dependency. The trial has completed treatment for three cats, all showing clinical improvements without significant side effects. Ainos aims to leverage these findings to strengthen its position in the $13 billion global pet dental health market by offering potential steroid-free or reduced treatments for chronic inflammatory diseases in companion animals. Ainos continues to advance its proprietary AI Nose and VELDONA technologies in its product pipeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ainos Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1029110) on May 19, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2536689144"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536689144\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2536689144?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-19 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536689144","market":"nz","top_or_hot":-1,"title":"Ainos Inc. Announces Breakthrough Interim Results in VELDONA Clinical Trial for Feline Chronic Gingivostomatitis, Signaling New Era in Companion Animal Immunotherapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ainos Inc. Announces Breakthrough Interim Results in VELDONA Clinical Trial for Feline Chronic Gingivostomatitis, Signaling New Era in Companion Animal Immunotherapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ainos Inc., a San Diego-based biotech company, has announced interim results from its ongoing clinical trial of VELDONA, a low-dose oral interferon therapy, for treating Feline Chronic Gingivostomatitis (FCGS), a chronic inflammatory condition in cats. The trial involves 30 cats and aims to assess inflammation scores, corticosteroid usage, and treatment safety. Early results show significant improvements in inflammation and a reduction in steroid dependency. The trial has completed treatment for three cats, all showing clinical improvements without significant side effects. Ainos aims to leverage these findings to strengthen its position in the $13 billion global pet dental health market by offering potential steroid-free or reduced treatments for chronic inflammatory diseases in companion animals. Ainos continues to advance its proprietary AI Nose and VELDONA technologies in its product pipeline.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ainos Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1029110) on May 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ainos Inc. Announces Breakthrough Interim Results in VELDONA Clinical Trial for Feline Chronic Gingivostomatitis, Signaling New Era in Companion Animal Immunotherapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAinos Inc. Announces Breakthrough Interim Results in VELDONA Clinical Trial for Feline Chronic Gingivostomatitis, Signaling New Era in Companion Animal Immunotherapy\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-19 20:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ainos Inc. Announces Breakthrough Interim Results in VELDONA Clinical Trial for Feline Chronic Gingivostomatitis, Signaling New Era in Companion Animal Immunotherapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ainos Inc., a San Diego-based biotech company, has announced interim results from its ongoing clinical trial of VELDONA, a low-dose oral interferon therapy, for treating Feline Chronic Gingivostomatitis (FCGS), a chronic inflammatory condition in cats. The trial involves 30 cats and aims to assess inflammation scores, corticosteroid usage, and treatment safety. Early results show significant improvements in inflammation and a reduction in steroid dependency. The trial has completed treatment for three cats, all showing clinical improvements without significant side effects. Ainos aims to leverage these findings to strengthen its position in the $13 billion global pet dental health market by offering potential steroid-free or reduced treatments for chronic inflammatory diseases in companion animals. Ainos continues to advance its proprietary AI Nose and VELDONA technologies in its product pipeline.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ainos Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1029110) on May 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AIMD","symbol_name":"AINOS Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nNDLpr4ZQ:1","article_id":"2536689144","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536689144","pubTimestamp":1747656148,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ainos Inc. Announces Breakthrough Interim Results in VELDONA Clinical Trial for Feline Chronic Gingivostomatitis, Signaling New Era in Companion Animal Immunotherapy. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ainos Inc. published the original content used to generate this news brief via ACCESS Newswire  on May 19, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AIMD":"AINOS Inc.","BK4139":"生物科技"},"translate_title":"Ainos Inc.宣布VELDONA治疗猫慢性牙龈口炎临床试验取得突破性中期结果，标志着伴侣动物免疫疗法的新时代","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIMD":0.9},"content_text":"Ainos Inc. Announces Breakthrough Interim Results in VELDONA Clinical Trial for Feline Chronic Gingivostomatitis, Signaling New Era in Companion Animal Immunotherapy\n    \n\n        Ainos Inc., a San Diego-based biotech company, has announced interim results from its ongoing clinical trial of VELDONA, a low-dose oral interferon therapy, for treating Feline Chronic Gingivostomatitis (FCGS), a chronic inflammatory condition in cats. The trial involves 30 cats and aims to assess inflammation scores, corticosteroid usage, and treatment safety. Early results show significant improvements in inflammation and a reduction in steroid dependency. The trial has completed treatment for three cats, all showing clinical improvements without significant side effects. Ainos aims to leverage these findings to strengthen its position in the $13 billion global pet dental health market by offering potential steroid-free or reduced treatments for chronic inflammatory diseases in companion animals. Ainos continues to advance its proprietary AI Nose and VELDONA technologies in its product pipeline.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ainos Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1029110) on May 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}